Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Forschungsstelle

INNOSUISSE

Projektnummer

17994.1 PFLS-LS

Projekttitel

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Projekttitel Englisch

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Kurzbeschreibung (Englisch)	Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Abstract (Deutsch)	More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.
Abstract (Englisch)	More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.